p53: Radiosensitivity and antiangiogenic effects

Molecular Genetics and Metabolism

Volumn 64, Issue 1, 1998, Pages 7-11

  Chiarugi, Vincenzo ^a   Cinelli, Marina ^a   Magnelli, Lucia ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ATAXIA TELANGIECTASIA; CELL CYCLE; DNA REPAIR; DNA STRAND BREAKAGE; HUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; SENESCENCE; SHORT SURVEY;

ATAXIA; ATAXIA TELANGIECTASIA;

EID: 0032075846     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1006/mgme.1998.2690     Document Type: Article

References (40)

1. Lane D P. The regulation of p53 function: Steiner Award Lecture. Int J Cancer. 57:1994;623-627.
2. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle D A, Smith S, Uziel T, Sfez S. A single ataxia telangiectasia gene with a product similar to PI3 kinase. Science. 268:1995;1749-1753.
3. Khanna K K, Beamish H, Yan J, Habson K, Williams R, Dunn I, Lavin M F. Nature of G1/S cell cycle checkpoint defect in ataxia telangiectasia. Oncogene. 11:1995;609-618.
4. Magnelli L, Ruggiero M, Chiarugi V. The old and the new in p53 functional regulation. Biochem Mol Med. 62:1997;3-10.
5. El-Deiry W S, Harper J W, O'Connor P M, Velculescu V E, Canman C E, Jackman J, Pietenpol J A, Burrel M, Hil D E, Wang Y, Wiman K G, Mercer W E, Kastan M B, Kohn K W, Elledge S J, Kinzler K W, Vogelstein B. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1994;1169-1174.
6. Artuso M, Esteve A, Bresil H, Vuillaume M, Hall J. The role of the ataxia telangiectasia gene in the p53, WAF1-CIP1 (p21)- and GADD45-mediated response to DNA damage produced by ionizing radiation. Oncogene. 11:1995;1427-1435.
7. Miyashita T, Krajewsky S, Krajewska M, Wang H G, Liebermann D A, Hoffman B, Reed J C. Tumor suppressor p53 is a regulator of bcl2 and bax gene expression in vitro and in vivo. Oncogene. 9:1994;1799-1805.
8. Nagata S. Apoptosis by death factor. Cell. 88:1997;355-365.
9. Lane D P. p53, guardian of the genome. Nature. 358:1992;15-16.
10. Sandell L L, Zakian V A. Loss of a yeast telomere: Arrest, recovery and chromosome loss. Cell. 75:1993;729-739.
11. Slichenmyer W J, Nelson W G, Slebos R J, Kastan M B. Loss of a p53-associated G1 checkpoint does not decrease cell survival, following DNA damage. Cancer Res. 53:1993;4164-4168.
12. Andreassen P R, Margolis R L. 2-Aminopurine overrides multiple cell cycle checkpoints in BHK cells. Proc Natl Acad Sci USA. 89:1992;2272-2276.
13. Guillouf C, Rosselli F, Krishnaraju K, Moustacchi E, Hoffman B, Liebermann D A. p53 involvement in control of G2 exit of the cell cycle: Role in DNA damage-induced apoptosis. Oncogene. 10:1995;2263-2270.
14. Skladanowski A, Larsen A K. Expression of wild-type p53 increases etoposide cytotoxicity in M1 myeloid leukemia cells by facilitated G2 to M transition: Implications for gene therapy. Cancer Res. 57:1997;818-823.
15. Paules R S, Levedakou E N, Wilson S J, Innes C L, Rhodes N, Tlsty T D, Galloway D A, Donehower L A, Tainsky M A, Kaufmann W K. Defective G2 checkpoint function in cells from individuals with familial cancer syndromes. Cancer Res. 55:1995;1763-1773.
16. Stewart N, Hicks G G, Paraskevas F, Mowat M. Evidence for a second cell cycle block at G2/M by p53. Oncogene. 10:1995;109-115.
17. Kaufmann W K, Paules R S. DNA damage and cell cycle checkpoints. FASEB J. 10:1996;238-247.
18. Xiong Y, Hannon G J, Zhang H, Casso D, Kobayashi R, Beach D. p21 is an universal inhibitor of cyclin kinases. Nature. 366:1993;701-704.
19. Aloni-Grinstein R, Schwartz D, Rotter V. Accumulation of wild-type p53 protein upon gamma-irradiation induces a G2 arrest-dependent immunoglobulin kappa light chain gene expression. EMBO J. 14:1995;1392-1401.
20. Linke S P, Clarkin K C, Wahl G M. p53 mediates permanent arrest over multiple cell cycles in response to gamma-irradiation. Cancer Res. 57:1997;1171-1179.
21. Bouffler S D, Kemp C J, Balmain A, Cox R. Spontaneous and ionizing radiation-induced chromosomal abnormalities in p53-deficient mice. Cancer Res. 55:1995;3883-3889.
22. Lee J M, Abrahamson J L, Kandel R, Donehower L A, Bernstein A. Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice. Oncogene. 9:1994;3731-3736.
23. Sands A T, Suraokar M B, Sanchez A, Marth J E, Donehower L A, Bradley A. p53 deficiency does not affect the accumulation of point mutations in a transgene target. Proc Natl Acad Sci USA. 92:1995;8517-8521.
24. Gupta N, Vij R, Haas-Kogan D A, Israel M A, Deen D F, Morgan W F. Cytogenetic damage and the radiation-induced G1-phase checkpoint. Radiat Res. 145:1996;289-298.
25. Murnane J P. Cell cycle regulation in response to DNA damage in mammalian cells: a historical perspective. Cancer Metastasis Rev. 14:1995;17-29.
26. Di Leonardo A, Linke S P, Clarkin K, Wahl G M. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 8:1994;2540-2551.
27. Noda A, Ning Y, Venable S F, Pereira-Smith O M, Smith J R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res. 211:1994;90-98.
28. Almasan A, Linke S P, Paulson T G, Huang L C, Wahl G M. Genetic instability as a consequence of inappropriate entry into and progression through S-phase. Cancer Metastasis Rev. 14:1995;59-73.
29. Levine A J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
30. Ozbun M A, Butel J S. Tumor suppressor p53 mutations and breast cancer: A critical analysis. Adv Cancer Res. 66:1995;71-141.
31. Dameron K M, Volpert O V, Tainsky M A, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 265:1994;1582-1584.
32. Volpert O V, Dameron K M, Bouck N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene. 14:1997;1495-1502.
33. Good D J, Polverini P J, Rastinejad F, Le Beau M M, Lemons R S, Frazier W A, Bouck N P. A Tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistiguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA. 87:1990;6624-6628.
34. Dameron K M, Volpert O V, Tainsky M A, Bouck N. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harbor Symp Quant Biol. 59:1994;483-489.
35. Zambetti G P, Levine A J. A comparison of the biological activities of wild-type and mutant p53. FASEB J. 7:1993;855-865.
36. Gately S, Twardowski P, Stack M S, Patrick M, Boggio L, Cundiff D L, Schnaper H W, Madison L, Volpert O, Bouck N, Enghild J, Kwaan H C, Soff G A. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res. 56:1996;4887-4990.
37. Muragaki Y, Timmons S, Griffith C M, Oh S P, Fadel B, Quertermous T, Olsen B R. Mouse col18-a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones. Proc Natl Acad Sci USA. 92:1995;8763-8767.
38. O'Reilly M S, Boehm T, Shing Y, Fukai N, Vasios G, Lane W S, Flynn E, Birkhead J R, Olsen B R, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:1997;277-285.
39. Boehm T, Folkma J, Browder T, O'Reilly M S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407.
40. Kerbel R S. A cancer therapy resistant to resistance. Nature. 390:1997;335-336.